Clinical trials: Intravenous Infusions
Advanced Solid Tumor
Study of CPI-200 in Patients With Advanced Tumors
This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3…
- Trial name
- NCT03953742
- Testing
- CPI-200
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Iron Deficiency Anemia, Chronic Kidney Disease
Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
The study is designed to determine the effects of an investigational drug Monofer in subjects with non-dialysis dependent chronic kidney disease (NDD-CKD) subjects and with iron deficiency anaemia (IDA).
- Trial name
- NCT01102413
- Testing
- Monofer, Iron Sulphate
- Where
- Denmark
- Volunteers
- 351 people
- Sponsor
- Pharmacosmos A/S
Healthy
A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.
- Trial name
- NCT05515588
- Testing
- BI 690517 (C-14), BI 690517
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hereditary Angioedema (HAE)
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent angioedema attacks in children 6 to 11 years of…
- Trial name
- NCT02052141
- Testing
- CINRYZE 500, CINRYZE 1000
- Where
- 8 sites in United States, Germany and 3 more
- Volunteers
- 12 people
- Sponsor
- Shire
Multiple Sclerosis
NOGO-A in Multiple Sclerosis FTIH
The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth. The trial is expected to involve approximately 36 patients.
- Trial name
- NCT01424423
- Testing
- GSK1223249
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Healthy
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.
- Trial name
- NCT02470702
- Testing
- Oritavancin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
Diagnostic Imaging
PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.
The study will be conducted as an open label, single-center, single dose and biodistribution study in patients with cancer or inflammation.
- Trial name
- NCT01297088
- Testing
- BAY86-9596
- Where
- 2 sites in Singapore
- Volunteers
- 24 people
- Sponsor
- Lantheus Biosciences Ltd.
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar
COVID-19, SARS-CoV-2
Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants
AZD3152 is being evaluated for administration to prevent COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD3152 as well as relevant data on the PK, PD (as the neutralising…
- Trial name
- NCT05932641
- Testing
- AZD3152 (Cohort 1), AZD3152 (Cohort 2), AZD3152 (Cohort 3)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Macular Edema
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
- Trial name
- NCT02103283
- Testing
- Teprotumumab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.
- Trial name
- NCT03885037
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 77 people
- Sponsor
- Pfizer
Iron-deficiency
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors
The primary purpose of the study is to evaluate the effect of IV iron isomaltoside 1000 compared with placebo on Hb in first-time female donors with p-ferritin below 30 µg/L
- Trial name
- NCT01895231
- Testing
- Iron isomaltoside 1000 (Monofer®)
- Where
- Denmark
- Volunteers
- 107 people
- Sponsor
- Pharmacosmos A/S
Epilepsy
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a…
- Trial name
- NCT01405508
- Testing
- Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion
- Where
- 17 sites in United States, Czechia and 2 more
- Volunteers
- 105 people
- Sponsor
- UCB Pharma
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal…
- Trial name
- NCT00069108
- Testing
- 5 FU, Leucovorin, Oxaliplatin
- Where
- 87 sites in United States, Belgium and 18 more
- Volunteers
- 627 people
- Sponsor
- Hoffmann-La Roche
COVID19 Pneumonia
Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients
A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in COVID-19 pneumonia patients
- Trial name
- NCT04565379
- Testing
- NuSepin® 0.1 mg, NuSepin® 0.2 mg
- Where
- 5 sites in Romania
- Volunteers
- 64 people
- Sponsor
- Shaperon
Pharmacology, Clinical
Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion
This study will investigate the absorption, distribution, metabolism and excretion after giving 2000 mg 14C-SLV334 via a 1-hour infusion. The absolute bioavailability will also be determined.
- Trial name
- NCT01044524
- Testing
- SLV 334
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Stable Atherothrombotic Disease
A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients
Reconstituted high density lipoprotein used in patients with acute coronary syndrome (ACS) may reduce atherosclerotic plaque burden, thereby reducing the risk of recurrent cardiovascular events.
- Trial name
- NCT01499420
- Testing
- CSL112 (reconstituted high density lipoprotein)
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- CSL Limited
Enteral Nutrition
Gastric Emptying Study After Administration of a High Caloric Sip Feed
Measurement of gastric emptying time of an oral nutritional supplement (ProvideXtra DRINK) by using the paracetamol absorption method in healthy volunteers.
- Trial name
- NCT00600678
- Testing
- ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi
Advanced Solid Tumor
A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
Primary Objective: To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of XRP6258 when given as a weekly 1-hour intravenous (i.v.) infusion for the first 4 consecutive weeks of each 5-week treatment…
- Trial name
- NCT01755390
- Testing
- Cabazitaxel (XRP6258)
- Where
- 2 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Sanofi
Advanced Cancer
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
The main purpose of this study is to evaluate the safety of the study drug known as Prexasertib (LY2606368) in participants with advanced cancer or cancer that has spread to other parts of the body.
- Trial name
- NCT02778126
- Testing
- [¹⁴C]Prexasertib, Prexasertib
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company